Side-by-side · Research reference
AdipotidevsP21
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED15/49 cited
BAnimal-MechanisticHUMAN-REVIEWED8/36 cited
Adipotide
Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only
IV · Systemic · Preclinical Protocols OnlyHossen 2013
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
01Mechanism of Action
Parameter
Adipotide
P21
Primary target
Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Pathway
CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
Downstream effect
Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Feedback intact?
N/A — Direct apoptotic mechanism, non-hormonal
—
Origin
Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Antibody development
—
—
02Dosage Protocols
Parameter
Adipotide
P21
Animal dose (mouse)
Low dose (not specified in abstract)Hossen 2013
Systemic injection in diet-induced obesity (DIO) models.Hossen 2013
—
Route
Intravenous (systemic injection)
Presumed subcutaneous or intraperitoneal (animal studies)
Frequency
Not specified in available data
—
Evidence basis
Preclinical animal models only
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Human data
None — no clinical trials reported
—
Human dosing
—
No established protocol
No clinical trial data available.
Animal models (mice)
—
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
Duration
—
Not specified
03Metabolic / Fat Loss Evidence
Parameter
Adipotide
P21
Primary fat target
White adipose tissue (all depots)
—
Body weight reduction
Significant reduction in DIO miceHossen 2013
Absolute values not provided in abstract.
—
Leptin levels
Significant decrease
Parallel to adipose mass reduction.
—
Effect on adipocytes
Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013
—
Ectopic fat
Reduction in ectopic fat depositionHossen 2013
Marker of dysfunctional adipose tissue / metabolic syndrome.
—
Species tested
Obese rhesus monkeys, DIO mice
—
Human translation
Unknown — no clinical trials
—
04Side Effects & Safety
Parameter
Adipotide
P21
Safety profile
Unknown — preclinical data only
—
Vascular selectivity
Targets adipose vasculature; off-target vascular effects unknown
—
Apoptotic mechanism risk
Pro-apoptotic payload may affect unintended tissues if selectivity incomplete
—
Kidney / liver toxicity
Not reported in available data
—
Immunogenicity
Not assessed in available data
—
Human safety data
—
None available
No clinical trials in humans.
Animal tolerability
—
Well-tolerated in mouse models; no toxicity reported in available abstracts
Theoretical risks
—
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
Absolute Contraindications
Adipotide
- ·Human use — not approved, no clinical safety data
P21
- ·Use in humans not validated
Relative Contraindications
Adipotide
- ·Any condition requiring intact adipose-tissue vascularisation
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
05Administration Protocol
Parameter
Adipotide
P21
1. Route
Intravenous injection (systemic) in preclinical models. No human protocols exist.
Not established. No FDA approval, no clinical trial data.
2. Formulation
Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
3. Preclinical dosing
Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013
—
4. Storage
Not specified — likely requires peptide-grade lyophilised storage and reconstitution.
—